Ironwood Pharmaceuticals, Inc. (IRDW), and Almirall, S.A. Wednesday said the European Commission has granted permission to market drug Constella for the treatment of irritable bowel syndrome with constipation, or IBS-C, in adults. This decision follows the positive recommendation for the drug received from the The European Medicines Agency in late September this year.
IBS, known to affect nearly 15 million adults in the European Union, is characterized by abdominal pain, discomfort, swelling or constipation. Until now, there are very few affective treatments for the disease in the European Union, said the companies in a statement.
Further, first launches of the drug in Europe are expected to occur in the first half of 2013.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.